These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20925434)

  • 1. Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist.
    Nikas SP; Alapafuja SO; Papanastasiou I; Paronis CA; Shukla VG; Papahatjis DP; Bowman AL; Halikhedkar A; Han X; Makriyannis A
    J Med Chem; 2010 Oct; 53(19):6996-7010. PubMed ID: 20925434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C1'-cycloalkyl side chain pharmacophore in tetrahydrocannabinols.
    Papahatjis DP; Nahmias VR; Nikas SP; Andreou T; Alapafuja SO; Tsotinis A; Guo J; Fan P; Makriyannis A
    J Med Chem; 2007 Aug; 50(17):4048-60. PubMed ID: 17672444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C1'-Azacycloalkyl Hexahydrocannabinols.
    Ho TC; Shimada N; Tius MA; Nikas SP; Zhang W; Makriyannis A
    J Org Chem; 2017 Aug; 82(15):7839-7849. PubMed ID: 28677397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel C-Ring-Hydroxy-Substituted Controlled Deactivation Cannabinergic Analogues.
    Kulkarni S; Nikas SP; Sharma R; Jiang S; Paronis CA; Leonard MZ; Zhang B; Honrao C; Mallipeddi S; Raghav JG; Benchama O; Järbe TU; Bergman J; Makriyannis A
    J Med Chem; 2016 Jul; 59(14):6903-19. PubMed ID: 27367336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.
    Khanolkar AD; Lu D; Ibrahim M; Duclos RI; Thakur GA; Malan TP; Porreca F; Veerappan V; Tian X; George C; Parrish DA; Papahatjis DP; Makriyannis A
    J Med Chem; 2007 Dec; 50(26):6493-500. PubMed ID: 18038967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice.
    Järbe TU; Tai S; LeMay BJ; Nikas SP; Shukla VG; Zvonok A; Makriyannis A
    Psychopharmacology (Berl); 2012 Mar; 220(2):417-26. PubMed ID: 21989802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor.
    Marriott KS; Huffman JW; Wiley JL; Martin BR
    Bioorg Med Chem; 2006 Apr; 14(7):2386-97. PubMed ID: 16321538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'.
    Papahatjis DP; Nikas SP; Kourouli T; Chari R; Xu W; Pertwee RG; Makriyannis A
    J Med Chem; 2003 Jul; 46(15):3221-9. PubMed ID: 12852753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols.
    Papahatjis DP; Kourouli T; Abadji V; Goutopoulos A; Makriyannis A
    J Med Chem; 1998 Mar; 41(7):1195-200. PubMed ID: 9544219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs.
    Busch-Petersen J; Hill WA; Fan P; Khanolkar A; Xie XQ; Tius MA; Makriyannis A
    J Med Chem; 1996 Sep; 39(19):3790-6. PubMed ID: 8809166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Selectivity of CB2 Cannabinoid Receptor Ligands at a Canonical and Noncanonical Pathway.
    Dhopeshwarkar A; Mackie K
    J Pharmacol Exp Ther; 2016 Aug; 358(2):342-51. PubMed ID: 27194477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
    Rao GK; Kaminski NE
    J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformationally constrained analogs of BAY 59-3074 as novel cannabinoid receptor ligands.
    Teng H; Thakur GA; Makriyannis A
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5999-6002. PubMed ID: 21880487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel cannabinol probes for CB1 and CB2 cannabinoid receptors.
    Mahadevan A; Siegel C; Martin BR; Abood ME; Beletskaya I; Razdan RK
    J Med Chem; 2000 Oct; 43(20):3778-85. PubMed ID: 11020293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel adamantyl cannabinoids as CB1 receptor probes.
    Thakur GA; Bajaj S; Paronis C; Peng Y; Bowman AL; Barak LS; Caron MG; Parrish D; Deschamps JR; Makriyannis A
    J Med Chem; 2013 May; 56(10):3904-21. PubMed ID: 23621789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity.
    Melvin LS; Milne GM; Johnson MR; Wilken GH; Howlett AC
    Drug Des Discov; 1995 Nov; 13(2):155-66. PubMed ID: 8872458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chain Substituted Cannabilactones with Selectivity for the CB2 Cannabinoid Receptor.
    Alapafuja SO; Nikas SP; Ho TC; Tong F; Benchama O; Makriyannis A
    Molecules; 2019 Oct; 24(19):. PubMed ID: 31581433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties.
    Cumella J; Hernández-Folgado L; Girón R; Sánchez E; Morales P; Hurst DP; Gómez-Cañas M; Gómez-Ruiz M; Pinto DC; Goya P; Reggio PH; Martin MI; Fernández-Ruiz J; Silva AM; Jagerovic N
    ChemMedChem; 2012 Mar; 7(3):452-63. PubMed ID: 22302767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing the carboxyester side chain in controlled deactivation (-)-δ(8)-tetrahydrocannabinols.
    Nikas SP; Sharma R; Paronis CA; Kulkarni S; Thakur GA; Hurst D; Wood JT; Gifford RS; Rajarshi G; Liu Y; Raghav JG; Guo JJ; Järbe TU; Reggio PH; Bergman J; Makriyannis A
    J Med Chem; 2015 Jan; 58(2):665-81. PubMed ID: 25470070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
    Dziadulewicz EK; Bevan SJ; Brain CT; Coote PR; Culshaw AJ; Davis AJ; Edwards LJ; Fisher AJ; Fox AJ; Gentry C; Groarke A; Hart TW; Huber W; James IF; Kesingland A; La Vecchia L; Loong Y; Lyothier I; McNair K; O'Farrell C; Peacock M; Portmann R; Schopfer U; Yaqoob M; Zadrobilek J
    J Med Chem; 2007 Aug; 50(16):3851-6. PubMed ID: 17630726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.